BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3848476)

  • 1. Aluminum bone disease. (A case study).
    Coleman S
    J Nephrol Nurs; 1985; 2(3):125-6. PubMed ID: 3848476
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH; Roodvoets AP; Van Groningen K
    Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 6. Aluminum-induced dialysis osteodystrophy: the demise of "Newcastle bone disease"?
    Kerr DN; Ward MK; Arze RS; Ramos JM; Grekas D; Parkinson IS; Ellis HA; Owen JP; Simpson W; Dewar J
    Kidney Int Suppl; 1986 Feb; 18():S58-64. PubMed ID: 3457998
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of dialysis encephalopathy with deferoxamine].
    Starkstein S; Berthier M; Nogués M; Leiguarda R
    Medicina (B Aires); 1986; 46(3):327-31. PubMed ID: 3574092
    [No Abstract]   [Full Text] [Related]  

  • 8. [Serum aluminum in hemodialysis patients. Relation to osteodystrophy, encephalopathy and aluminum hydroxide consumption].
    Nielsen LP; Heaf JG
    Ugeskr Laeger; 1983 May; 145(18):1363-7. PubMed ID: 6868163
    [No Abstract]   [Full Text] [Related]  

  • 9. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU; Becker GJ; Kincaid-Smith PS
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract]   [Full Text] [Related]  

  • 11. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aluminum-induced osteomalacia in chronic hemodialysis].
    Smetana S; Popovtzer MM; Bar-Khayim Y
    Harefuah; 1987 Jun; 112(12):595-7. PubMed ID: 3428727
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 14. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of aluminium toxicity in a 'low incidence' area.
    Winney RJ; Cowie JF; Cumming AD; Short AI; Smith GD; Robson JS
    Contrib Nephrol; 1984; 38():47-58. PubMed ID: 6713900
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bone mineral content and treatment with deferoxamine in patients under chronic hemodialysis].
    Zanchetta JR; Bogado CE; Zuchini A; Firmat J
    Medicina (B Aires); 1992; 52(2):184-5. PubMed ID: 1308914
    [No Abstract]   [Full Text] [Related]  

  • 17. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
    Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA
    ASAIO Trans; 1986; 32(1):198-200. PubMed ID: 3778712
    [No Abstract]   [Full Text] [Related]  

  • 18. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide.
    Griswold WR; Reznik V; Mendoza SA; Trauner D; Alfrey AC
    Pediatrics; 1983 Jan; 71(1):56-8. PubMed ID: 6848980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aluminum and iron deposition in dialysis patients].
    Kashiwagi T; Kurihara S
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():400-5. PubMed ID: 15250334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.